For a generation of young women in England, cervical cancer has effectively been erased. Between 2020 and 2024, not a single woman between the ages of 20 and 24 died from the disease across the entire country. Based on historical death rates, researchers had expected 23.1 deaths in that age group over that period.
That figure, zero, is not a rounding artifact or a statistical blip. It’s the result of a decision made more than a decade earlier, when the UK chose to offer a vaccine to 12- and 13-year-old girls in school. The cohort that received those shots first is now in their mid-to-late twenties, and the data is now old enough to show what happened to them. The answer, published in June 2026 by researchers from Queen Mary University of London, is unlike anything seen before in cancer prevention research.
The study, published on June 17, 2026 in The Lancet, analyzed population-based mortality data from across England going back to 2001. It is the first national study to demonstrate that HPV vaccination doesn’t just prevent precancerous changes or reduce cancer diagnoses – it prevents deaths. The lead author, Professor Peter Sasieni, Professor of Cancer Epidemiology and joint lead of the Centre for Cancer Screening, Prevention and Early Diagnosis at the Wolfson Institute of Population Health, Queen Mary University of London, described the finding plainly: “It’s incredible to think that a single jab can almost eliminate a particular type of cancer.”
What the Data Actually Shows About HPV Vaccination and Cervical Cancer
England introduced its national HPV vaccination program in 2008 for girls aged 12 to 13, with a catch-up campaign running from 2008 to 2010 for girls aged 14 to 18. Before the COVID-19 pandemic, coverage in England exceeded 80% across all adolescents identified as eligible, well above rates seen in most comparable countries. The 2026 study focused specifically on whether that investment translated into fewer women dying.
HPV vaccination and cervical cancer elimination have long been linked in theory, but evidence of vaccination’s effect on mortality had been scarce. The England data changes that. Researchers found that no cervical cancer deaths were recorded among women aged 20 to 24 between 2020 and 2024 – the first time such a record had been achieved in a five-year period. The study estimated that around 23 deaths would have been expected in this age group if vaccination had not been introduced.
The protection was strongest in the group that got vaccinated earliest. The study was led by Professor Peter Sasieni, who has spent decades researching cervical screening and HPV infection and was awarded a CBE in 2025 for services to cancer early detection and prevention. His team found that vaccination is critical because HPV is one of the most common sexually transmitted infections, with around 80% of people expected to contract it during their lifetime if unvaccinated.
Women vaccinated at ages 12 to 13, before most had any exposure to the virus, showed the most dramatic protection. In the early 2000s, roughly 50 women under the age of 35 were dying of cervical cancer in England every year. Almost all cervical cancers are caused by HPV, and between 2020 and 2024, the vaccine brought deaths in the 20- to 24-year-old age group to zero.
The benefit was measurable in older vaccinated women too, though it was smaller. The Lancet analysis found no cervical cancer deaths among women aged 20 to 24 between 2020 and 2024, and researchers estimate the HPV vaccination program has already prevented around 200 cervical cancer deaths in England, with many more lives expected to be saved as vaccinated women grow older. For women aged 25 to 29 – a group that includes some who were vaccinated slightly later, during the catch-up campaign – mortality dropped by 69% compared to what models would have predicted without the program.
Why Age at Vaccination Makes Such a Large Difference
The HPV vaccine protects against several cancer-causing strains of the virus, particularly those responsible for cervical cancer. It works by prompting the body’s immune system to produce antibodies that can neutralize the virus before infection occurs. That last phrase carries most of the weight. The vaccine doesn’t clear an existing infection – it prevents one from taking hold in the first place.
The Lancet study makes clear that ages 12 to 13 are the point at which vaccination produces the greatest benefit: the immune response is strongest, and vaccination before any HPV exposure confers the most complete protection. According to the CDC, the HPV vaccine works best when given before any exposure to HPV. Girls vaccinated in early adolescence, when the immune system also generates a particularly robust antibody response, get a dual advantage.
Girls who received the vaccine during the catch-up program at ages 14 to 18 showed lower reductions in cervical cancer mortality than those vaccinated at 12 to 13. By the mid-teen years, some had likely already encountered one or more HPV strains, limiting how much the vaccine could do. That gap in protection is exactly why the 12-to-13 window matters, and why pediatric vaccination programs deliver results that catch-up efforts cannot fully replicate.
Today’s standard HPV vaccine, Gardasil 9, protects against nine HPV types, including types 16 and 18 – the strains responsible for the majority of cervical cancers – as well as types 31, 33, 45, 52, and 58. Infection with HPV causes nearly 100% of cervical cancers. Types 16 and 18 together account for approximately 66% of cervical cancers worldwide, according to the CDC, with type 16 alone responsible for roughly half of all cases. That dominance of two strains is why broad-spectrum protection against multiple types matters – and why Gardasil 9’s additional five strains add meaningful coverage on top of the core protection.
The Global Gap: Where Vaccination Is Falling Behind
England’s results are extraordinary, but they depend on something most of the world hasn’t yet achieved: high vaccination coverage sustained over years. HPV vaccination rates in England have since fallen below the level the WHO says is needed to eliminate cervical cancer, according to UK Health Security Agency data for the 2024-25 academic year.
Globally, the picture is even more concerning. According to the American Cancer Society, around 350,000 women die from cervical cancer every year globally – a number that the same organization notes is preventable when women receive the HPV vaccine and recommended screening. The WHO’s targets for cervical cancer elimination by 2030 include vaccinating 90% of girls by age 15, a bar that most countries haven’t come close to clearing. Globally, an estimated 662,301 new cervical cancer cases and 348,874 deaths occurred in 2022.
Coverage among adolescent girls worldwide lags dramatically. In England, HPV vaccination rates for Year 8 girls stood at 71.7% in the 2024-25 academic year, down from rates approaching 90% before the COVID-19 pandemic, according to the UK Health Security Agency – well below the WHO’s 90% threshold for elimination. If that trend continues, the gains documented in the 2026 Lancet study could erode in future cohorts. Globally, first-dose coverage among girls by age 15 was just 21% in 2024, according to researchers at Johns Hopkins – less than a quarter of the WHO’s 90% target.
The study itself carries a methodological note that researchers have been transparent about. The analysis relied on population-level vaccination coverage data instead of individual-level status, researchers had access to mortality data in five-year age groups only rather than single-year cohorts, and the study assumed no herd protection among unvaccinated women within birth cohorts. Population-level studies like this one can’t establish causation with the same certainty as a randomized controlled trial. But when zero deaths occur in a cohort where 23 were expected – and when the pattern follows precisely the vaccination rollout timeline – the direction of the evidence is clear.
Public health has been waiting two decades for signs that HPV vaccination prevents deaths, not only precancerous lesions and cancer diagnoses. England’s data is the first national-scale evidence that it does.
Read More: Three Lifestyle Changes That Could Prevent Nearly 40% of Cancers
What This Means for You
The most actionable piece of information from this study has a narrow window: HPV vaccination at ages 12 to 13 produces the strongest protection, before the immune response weakens with age and before any likelihood of exposure. If you have a child approaching that age, confirming their eligibility and scheduling through your pediatrician or family doctor is the single most important step you can take. In the US, the CDC recommends the two-dose series for children aged 11 to 12. Those who miss the early window can still benefit from vaccination up to age 26, and adults aged 27 to 45 can discuss the option with a doctor, though the benefit diminishes as prior exposure becomes more likely.
For adults who are already past vaccination age, the most effective tool remains regular cervical screening. Pap tests (which check for abnormal cervical cells) and HPV tests (which detect the presence of high-risk virus strains) catch changes before they become cancer. According to the American Cancer Society, the death rate from cervical cancer has decreased by as much as 70% since the 1950s, though those decreases are primarily in high-income countries. Screening remains essential even for vaccinated women, since current vaccines don’t cover every cancer-causing HPV strain. The England study shows what’s possible when vaccination coverage is high and sustained. Maintaining that coverage – and expanding it globally – is what stands between the current 350,000 annual deaths worldwide and what researchers now know is achievable.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: These 5 Early Signs of Vaginal Cancer Should Never Be Ignored